Trans-sodium crocetinate - Diffusion Pharmaceuticals

Drug Profile

Trans-sodium crocetinate - Diffusion Pharmaceuticals

Alternative Names: Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC

Latest Information Update: 05 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Virginia
  • Developer Diffusion Pharmaceuticals
  • Class Antineoplastics; Carotenoids; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen compound modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Preclinical Brain metastases; Pancreatic cancer; Stroke
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 01 Feb 2018 Diffusion Pharmaceuticals receives two patent allowance for method of use and composition of matter of trans-sodium crocetinate in USA
  • 01 Feb 2018 Diffusion Pharmaceuticals plans the phase II trials for Pancreatic cancer and Brain metastases
  • 24 Jan 2018 Diffusion Pharmaceuticals, in collaboration with the University of California Los Angeles and the University of Virginia, plans a phase II PHAST-TSC trial for Stroke in USA in late 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top